Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Ascendis Pharma Growth Disorders A/s

Clinical trials sponsored by Ascendis Pharma Growth Disorders A/s, explained in plain language.

Ascendis Pharma ASND NASDAQ

Biopharmaceutical company developing therapies for rare endocrine disorders.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 2 Completed 1

New weekly injection shows promise for boosting growth in kids with dwarfism

Disease control Completed

This study tested a once-weekly injection called TransCon CNP in 84 children aged 2 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it safely increases growth rate over a year compared to a placebo. After the first year, all children could rece…

Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control

Last updated Jul 16, 2026 00:00 UTC